Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-31
2006-10-31
Andres, Janet L. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S369000
Reexamination Certificate
active
07129267
ABSTRACT:
The effect of EPO on the phosphorylation of the EPO receptor, the activation of the MAP Kinase pathway, and the expression of SHP-1 were analyzed. EPO was observed to cause a decrease in the expression of its negative regulator SHP-1. The decrease observed at both the mRNA and protein level was dose dependent and persisted as long as 24 hr following EPO treatment. EPO can down regulate the expression of its own negative regulator as a means for increased potency in neurons. Assays were generated to identify compounds that are useful in regulating SHP1 activity in neural cells.
REFERENCES:
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5688679 (1997-11-01), Powell
patent: 5965558 (1999-10-01), Mjalli et al.
patent: 6165783 (2000-12-01), Weiss et al.
patent: 6261279 (2001-07-01), Demopulos et al.
patent: 0 640 619 (1995-03-01), None
patent: 1 064 951 (2001-01-01), None
patent: WO 94/12650 (1994-06-01), None
patent: WO 98/05363 (1998-02-01), None
patent: WO 99/05268 (1999-02-01), None
patent: WO 99/05440 (1999-02-01), None
patent: WO 99/11781 (1999-03-01), None
patent: WO 99/38890 (1999-08-01), None
patent: WO 99/66054 (1999-12-01), None
patent: WO 01/75164 (2001-10-01), None
Brines ML et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci, USA, Sep. 12, 2000, 97(19): 10526-10531.
Renzi MJ et al. Erythropoietin down regulates SHP1 and induces a sustained activation of ERK1/ERK2 in primary cortical neurons. Blood, Nov. 16, 2001, 98(11 part 1): 77a, meeting abstract.
Siren AL et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci, USA, Mar. 27, 2001, 98(7): 4044-4049.
Copy of the PCT International Search Report dated Oct. 30, 2003 (PCT/US03/07200).
Barbone, F.P., et al., “New epoetin molecules and novel therapeutic approaches,”Nephrol Dial Transplant, 1999, 14(Suppl. 2), 80-84.
Bittorf, T., et al., “SHP1 protein tyrosine phosphatase negatively modulates erythroid differentiation and suppression of apoptosis in J2E erythroleukemic cells,”Biol. Chem., Oct. 1999, 380, 1201-1209.
Horvat, A., et al., “A novel role for protein tyrosine phosphatase SHP in controlling glial activation in thenormal and injured nervous system,”J. Neurosci., 2001, 21, 865-874.
Alafaci, et al., “Effect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhage,”Eur. J. Pharmacol., 2000, 406, 219-255.
Alessandrini, A., et al., “MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia,”PNASUSA, 1999, 96, 12866-12869.
Bernaudin, M., et al., “A potential role for erythropoietin in focal permanent cerebral ischemia in mice,”J. of Cereb. Blood Flow&Metab., 1999, 19, 643-651.
Bittorf, T., et al., “Induction of erythroid proliferation and differentiation by a trophoblast-specific cytokine involves activation of the JAK/STAT pathway,”J. Mol. Endocrinol., 2000, 25, 253-262.
Brines, M.L., et al., “Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury,”PNAS USA, 2000, 97, 10526-10531.
Brummelkamp, T.R., et al., “A system for stable expression of short interfering RNAs in mammalian cells,”Science, Apr. 19, 2002, 296, 550-553.
Cui, Y., et al., “Regulation of neutrophil responses by phosphotyrosine phosphatase,”J. of Immunol., 1994, 152, 5420.
Damen, J.E., et al., “Erythropoietin stimulates the tyrosine phosphorylation of Shc and its association with Grb2 and a 145-Kd tyrosine phosphorylated protein,”Blood, Oct. 15, 1993, 82(8), 2296-2303.
Digicaylioglu, M., et al., “Erythropoietin-mediated neuroprotection involved cross-talk between Jak2 and NF-Kb signaling cascades,”Nature, Aug. 9, 2001, 415, 641-647.
Digicaylioglu, M., et al., “Localization of specific erythropoietin binding sites in defined areas of the mouse brain,”Proc. Natl. Acad. Sci. USA, Apr. 1995, 92, 3717-3720.
Elbashir, S.M., et al., “RNA interference is mediated by 21- and 22-nucleotide RNAs,”Genes&Dev., 2001, 15, 188-200.
Fire, A., et al., “Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans,”Nature, Feb. 19, 1998, 391, 806-811.
Gautier, C., et al., “α-DNA IV: α-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physicochemical properties and poly (rA) binding,”Nucleic Acids Res., 1987, 15(16), 6625-6641.
Goeddel, Gene Expression Technology: Methods in Enzymology,Academic Press, San Diego, CA, 1990, 185.
Goodman, et al.,The Pharmacological Basis of Therapeutics, 6thEd., p. 244.
Hammond, S.M., et al., “An RNA-directed nuclease mediates post-transcriptional gene silencing inDrosophilacells,”Nature, Mar. 16, 2000, 404, 293-296.
Hanisch, U.-K., et al., “The protein tyrosine kinase inhibitor AG126 prevents the massive microglial cytokine induction by pneumococcal cells walls,”Eur. J. Immunol., 2001, 31, 2104-2115.
Inoue, H., et al., “Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H,”FEBS Lett., 1987, 215, 327-330.
Inoue, H., et al., “Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucleotides,” XP000570336,Nucleic Acids Res., 1987, 15(15), 6131-6148.
Juul, S.E., et al., “Erythropoietin and erythropoietin receptor in the developing human central nervous system,”Pediatr. Res., 1998, 43(1), 40-49.
Karminski-Zamola, G., et al., “Synthesis of some furyl- and thienylacrylates or diacrylates and acrylic acids by the palladium catalysed vinylation of substituted bromofurans and bromothiophenes,”Heterocycles, 1994, 38(4), 759-767.
Komatsu, N., et al., “Establishment and characterization of an erythropoietin-dependent subline, UT-7/EPO, derived from human leukemia cell line, UT-7,”Blood, Jul. 15, 1993, 82(2), 456-464.
Koshimura, K., et al., “Effects of erythropoietin on neuronal activity,”J. of Neurochem., 1999, 72, 2565-2572.
Krautwald, S., et al., “Involvement of the protein tyrosine phosphatase SHP-1 in RAS-mediated activation of the mitogen-activated protein kinase pathway,”Mol. And Cell. Biol., Nov. 1996, 16(11), 5955-5963.
Lam, K.S., “Application of combinatorial library methods in cancer research and drug discovery,”Anti-Cancer Drug Des., 1997, 12, 145-167.
Lanzetta, P.A., et al., “An improved assay for nanomole amounts of inorganic phosphate,”Anal. Biochem., 1979, 100, 95-97.
Lau, L.T., et al., “Astrocytes produce and release interleukin-1, interleukin-6, tumor necrosis factor alpha and interferon-gamma following traumatic and metabolic injury,”J. of Neurotrauma, 2001, 18(3), 351-359.
Lecoq-Lafon, C., et al., “Erythropoietin induces the tyrosine phosphorylation of GAB1 and its association with SHC, SHP2, SHIP, and phosphatidylinositol 3-kinase,”Blood, Apr. 15, 1999, 93(8), 2578-2585.
Lue, et al., “Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's Disease: identification of a cellular activation mechanism,”Exp. Neurol., 2001, 171, 29-45.
Male{hacek over (s)}ević, M., et al., “Photosynthesis of heteropolycyclic diquinolones twofold photodehydrohalogeneration reaction of benzo[1,2-b:4,5-b']dithiophene- and dithieno[3,2,-b:2′,3′-d]thiophenedicarboxanilides,”Heterocycles, 1995, 41(12), 2691-2699.
Masuda, S., et al., “Functional erythropoietin receptor of the cells with neural characteristics: comparison with receptor properties of erythroid cells,”J. Biol. Chem., May 25, 1993, 268(15), 11208-11216.
Mauschitz, R., et al., “Self-regulation of the endothelin receptor system in choriocarcinoma cells,”Biochem. et Biophys. Acta, 2000, 150
Farrell Francis X.
Jolliffe Linda
Renzi Michael
Thirumalai Navneeth
Andres Janet L.
Ballard Kimberly A.
Janssen Pharmaceutica N.V.
LandOfFree
Methods for SHP1 mediated neuroprotection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for SHP1 mediated neuroprotection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for SHP1 mediated neuroprotection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3616660